Ceftibuten/clavulanic acid - Achaogen
Alternative Names: ACHN-383; ACHN-789; C-Scape; Ceftibuten/Clavulanate; Ceftibuten/clavulanic-acid; Clavulanate/Ceftibuten; Clavulanic-acid/CeftibutenLatest Information Update: 28 Aug 2022
Price :
$50 *
At a glance
- Originator Achaogen
- Class Antibacterials; Beta-lactams
- Mechanism of Action Beta lactamase inhibitors; Cell wall inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Urinary tract infections
Most Recent Events
- 28 Aug 2022 No recent reports of development identified for phase-I development in Urinary-tract-infections(In volunteers, Complicated) in Australia (PO, Capsule)
- 13 Aug 2019 Ad-hoc Complicated Urinary tract infections: Modified Intro, added qualifier Complicated to dev table and related HEs
- 28 Mar 2019 Achaogen plans a phase I pharmacology trial for Ceftibuten/clavulanic acid